Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU SCOPE Project Will Harmonize Pharmacovigilance, Benefit Industry

This article was originally published in The Pink Sheet Daily

Executive Summary

The EU SCOPE pharmacovigilance project will harmonize practices across the 28 member states, thereby cutting the administrative and cost burden for pharmaceutical manufacturers.

You may also be interested in...



European Notebook Notes Arrival Of CHMP Minutes And Biosimilar MAbs

CHMP has released for the first time the minutes of its meeting, and EMA has set up a new pharmacovigilance cluster with the FDA. A biosimilar infliximab product from Hospira and Alvogen has become the first biosimilar monoclonal antibody launched in Europe.

European Generics Applications Fall, As EMA’s Interim Report Hopes To Herald Funding Renewal

European Commission intervention has stopped duplicate generic applications. EMA hopes to end its budget row with the EU Parliament by focusing on transparency and conflict of interest disclosures.

Lacking "Mediator," EC Tightens Pharmacovigilance Proposals

European Commission's surprise update of the pharmacovigilance rules is included in its review of the information to patients legislation, but industry's biggest concern may be the failure to address the role of social media.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel